Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

被引：0
作者：
Job A. J. Verdonschot
João Pedro Ferreira
Pierpaolo Pellicori
Hans-Peter Brunner-La Rocca
Andrew L. Clark
Franco Cosmi
Joe Cuthbert
Nicolas Girerd
Beatrice Mariottoni
Johannes Petutschnigg
Patrick Rossignol
John G. F. Cleland
Faiez Zannad
Stephane R. B. Heymans
机构：
[1] Maastricht University Medical Center,Department of Clinical Genetics
[2] Centre d’Investigations Cliniques Plurithématique 1433,Robertson Centre for Biostatistics, Institute of Health and Wellbeing
[3] Université de Lorraine,Department of Cardiology
[4] Institut National de la Santé et de la Recherche Médicale 1116,Department of Cardiology
[5] Centre Hospitalier Régional Universitaire de Nancy,Department of Cardiology
[6] French Clinical Research Infrastructure Network,Department of Internal Medicine and Cardiology
[7] Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists,undefined
[8] University of Glasgow,undefined
[9] Glasgow Royal Infirmary,undefined
[10] Maastricht University Medical Center (MUMC+),undefined
[11] University of Hull,undefined
[12] Castle Hill Hospital,undefined
[13] Cortona Hospital,undefined
[14] Campus Virchow Klinikum,undefined
[15] Charite´ University Medicine Berlin,undefined
[16] Berlin Institute of Health (BIH),undefined
[17] and German Centre for Cardiovascular research (DZHK),undefined
[18] Partner Site Berlin,undefined
来源：
Cardiovascular Diabetology | / 20卷
关键词：
Diabetes; Biomarker; Heart failure; Spironolactone; Fibrosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 195 条
  • [1] Domanski M(2003)The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial J Am Coll Cardiol 42 914-922
  • [2] Krause-Steinrauf H(2019)In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study Diabetologia 62 1998-2006
  • [3] Deedwania P(2019)Using a targeted proteomics chip to explore pathophysiological pathways for incident diabetes—the Malmö preventive project Sci Rep 9 272-242
  • [4] Follmann D(2020)Distinct pathological pathways in patients with heart failure and diabetes JACC Heart Fail 8 234-1723
  • [5] Ghali JK(2020)Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial Eur J Heart Fail 22 1711-696
  • [6] Gilbert E(2020)The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial Eur Heart J 42 684-1694
  • [7] Haffner S(2004)Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes Diabetologia 47 1687-921
  • [8] Katz R(2010)Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure Am Heart J 160 915-277
  • [9] Lindenfeld J(2021)Proteomic and mechanistic analysis of spironolactone in patients at risk for HF JACC Heart Fail 9 268-297
  • [10] Lowes BD(2006)GDF15, a cardioprotective TGF-beta superfamily protein Circ Res 98 294-734
12345678910